Cara Therapeutics, Inc. (CARA) Covered Calls

Cara Therapeutics, Inc. covered calls Cara Therapeutics Inc is a clinical-stage biopharmaceutical company developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors.

There are no covered calls available for Cara Therapeutics, Inc..

Born To Sell's covered call screener gives you full search capabilities so you can find stocks and ETFs that make good covered call candidates.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

CARA Therapeutics, Inc. is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain, inflammation and pruritus. The company involves in the developing of novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated efficacy in patients with moderate-to-severe pain without undesirable side effects typically associated with currently available pain therapeutics. Its product candidate includes I.V. CR845, Oral CR845 and CR701. CARA Therapeutics was founded by Derek T. Chalmers, Michael E. Lewis and Frédérique Menzaghi on July 2, 2004 and is headquartered in Shelton, CT.